

(12) International Application Status Report

Received at International Bureau: 10 January 2021 (10.01.2021)

Information valid as of: 23 February 2021 (23.02.2021)

Report generated on: 25 September 2023 (25.09.2023)

(10) Publication number:

WO2021/133809

(43) Publication date:

01 July 2021 (01.07.2021)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/US2020/066629

(22) Filing Date:

22 December 2020 (22.12.2020)

(25) Filing language:

English (EN)

(31) Priority number(s):

62/953,030 (US)

(31) Priority date(s):

23 December 2019 (23.12.2019)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

C07D 401/14 (2006.01); **C07D 471/04** (2006.01); **C07D 491/04** (2006.01); **C07D 491/08** (2006.01); **C07D 491/10** (2006.01); **C07D 519/00** (2006.01); **A61P 35/00** (2006.01); **A61K 31/506** (2006.01)

(71) Applicant(s):

BLUEPRINT MEDICINES CORPORATION [US/US]; 45 Sidney Street Cambridge, MA 02139 (US) *(for all designated states)*

(72) Inventor(s):

CAMPBELL, John, Emmerson; 45 Sidney Street Cambridge, MA 02139 (US)

DINEEN, Thomas, A.; 45 Sidney Street Cambridge, MA 02139 (US)

BROOIJMANS, Natasja; 45 Sidney Street Cambridge, MA 02139 (US)

BRUBAKER, Jason, D.; 45 Sidney Street Cambridge, MA 02139 (US)

ENO, Meredith, Suzanne; 45 Sidney Street Cambridge, MA 02139 (US)

KIM, Joseph, L.; 45 Sidney Street Cambridge, MA 02139 (US)

OZEN, Aysegul; 45 Sidney Street Cambridge, MA 02139 (US)

PEROLA, Emanuele; 45 Sidney Street Cambridge, MA 02139 (US)

WILLIAMS, Brett, D.; 45 Sidney Street Cambridge, MA 02139 (US)

WILSON, Douglas; 45 Sidney Street Cambridge, MA 02139 (US)

WILSON, Kevin, J.; 45 Sidney Street Cambridge, MA 02139 (US)

DE SAVI, Christopher; 45 Sidney Street Cambridge, MA 02139 (US)

(74) Agent(s):

DAVIS, Steven, G.; McCarter & English, LLP 265 Franklin Street Boston, MA 02110 (US)

(54) Title (EN): INHIBITORS OF MUTANT FORMS OF EGFR

(54) Title (FR): INHIBITEURS DE FORMES MUTANTES DE L'EGFR

(57) Abstract:

(EN): The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt thereof useful for treating a cancer.

(FR): L'invention concerne un composé représenté par la formule développée (I) : ou un sel pharmaceutiquement acceptable de celui-ci utile pour le traitement d'un cancer.

International search report:

Received at International Bureau: 16 February 2021 (16.02.2021) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:

Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate

Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii))